On May 7, 2025, Gilead Sciences announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, becoming the latest company to announce spending plans in reaction to President Donald Trump’s tariff policy.

The new investments will supplement an already planned spending of $21 billion to boost U.S. manufacturing and research and development through 2030, the drugmaker said.

These investments will be used for new technology, building three new facilities and upgrading three existing sites, it said.

Gilead said the additional $11 billion would lead to at least 800 new direct jobs and support more than 2,200 indirect jobs by 2028.

The company said its investments would create $43 billion in value to the U.S. economy over the next five years.